House lawmakers urge CMS to drop planned 340B cuts

AHA News

A bipartisan group of 228 House lawmakers yesterday urged the Centers for Medicare & Medicaid Services (CMS) to abandon its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program.

“Given the important role that the 340B program plays in our communities, we... read more

Topic: Advocacy and Public Policy
Tags: Drug Pricing Program, advocacy

AHA opposes any further delay of 340B drug ceiling price rule

AHA News Now

The AHA today urged the Health Resources and Services Administration to implement its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers without delay. “Delaying the implementation of the ceiling price and CMPs an additional nine months – from Oct. 1, 2017 to July 1,... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, drug prices

Protect 340B and Preserve the Safety Net

Blog

The panel that advises the Centers for Medicare & Medicaid Services on hospital outpatient payments sent a clear signal to the agency this week: Don’t shortchange patients’ access to vital pharmaceuticals by cutting the 340B Drug Pricing Program. CMS’s Advisory Panel on Hospital Outpatient Payment... read more

Topics: Access and Coverage, Advocacy and Public Policy
Tags: Drug Pricing Program, advocacy, access

House holds hearing on 340B Drug Pricing Program

AHA News Now

The House Energy & Commerce Subcommittee on Oversight and Investigations today held a hearing to review the Health Resources and Services Administration’s oversight of the 340B Drug Pricing Program and how the program impacts patients, providers, manufacturers and other stakeholders. In comments submitted... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program

CMS releases 2018 outpatient PPS and physician payment proposed rules

AHA News

The AHA July 13 criticized proposed deep cuts to how much the Centers for Medicare & Medicaid Services reimburses hospitals for drugs acquired under the 340B Drug Pricing Program and proposes changes to site-neutral payment policies under Section 603 of the 2015 Bipartisan Budget Act. The provisions are... read more

Topics: Quality and Patient Safety, Advocacy and Public Policy
Tags: 340B, site neutral payment, Drug Pricing Program, Medicare, regulation

HRSA further delays effective date of final rule on 340B drug ceiling prices

AHA News Now

The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate. The rule was set to take effect March 21... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, regulation, drug prices

AHA Stat blog: Congress should protect the 340B program

AHA News Now

“Congress should preserve the 340B Drug Pricing Program and protect patients and communities,” writes AHA Executive Vice President Tom Nickels in an AHA Stat blog post. He notes, “Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, drug prices

HRSA proposed rule would establish dispute resolution process for 340B program

AHA News Now

The Health Resources and Services Administration today released a proposed rule that would implement an Affordable Care Act provision requiring a binding administrative dispute resolution process for 340B Drug Pricing Program participants who claim they have been overcharged for drugs purchased through... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, regulation

Hospitals, not pharmaceutical manufacturers, are preserving and protecting the safety net

Blog

A group financed by the pharmaceutical industry is hosting a meeting today on the 340B Drug Pricing Program with the goal of “Preserving the True Safety Net.” But what the meeting really will be about is the pharmaceutical industry – with their skyrocketing prescription drug prices and huge profits –... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, Community benefit, access, drug prices

Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs

Blog

The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.

Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a program... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

Keyword Search

Date